Alzheimer s Research & Therapy · 2019 · 36 citations · 44 references
Life SciencesNeurobiologyNeuroscienceImmunizationNeurodegenerationVaccinologyAlzheimer DiseaseAmyloid FormationNeurodegenerative DiseasesNeurodegenerative DisordersProtein AggregationTau PathologyAdjuvant DeliveryAlzheimer Disease Tau PathologyAmyloid Beta-targeted TherapyTau AggregationTau-targeted TherapyTherapeutic Targeting Of AmyloidTransgenic MiceVectored Vaccines
Abstract Background Alzheimer disease (AD) is characterized by the accumulation of beta-amyloid (Aβ) plaques and neurofibrillary tangles composed of hyperphosphorylated tau, which together lead to neurodegeneration and cognitive decline. Current therapeutic approaches have primarily aimed to reduce pathological aggregates of either Aβ or tau, yet phase 3 clinical trials of these approaches have thus far failed to delay disease progression in humans. Strong preclinical evidence indicates that these two abnormally aggregated proteins interact synergistically to drive downstream neurodegeneration. Therefore, combinatorial therapies that concurrently target both Aβ and tau might be needed for effective disease modification. Methods A combinatorial vaccination approach was designed to concurrently target both Aβ and tau pathologies. Tau22/5xFAD (T5x) bigenic mice that develop both pathological Aβ and tau aggregates were injected intramuscularly with a mixture of two MultiTEP epitope vaccines: AV-1959R and AV-1980R, targeting Aβ and tau, respectively, and formulated in Advax CpG , a potent polysaccharide adjuvant. Antibody responses of vaccinated animals were measured by ELISA, and neuropathological changes were determined in brain homogenates of vaccinated and control mice using ELISA and Meso Scale Discovery (MSD) multiplex assays. Results T5x mice immunized with a mixture of Aβ- and tau-targeting vaccines generated high Aβ- and tau-specific antibody titers that recognized senile plaques and neurofibrillary tangles/neuropil threads in human AD brain sections. Production of these antibodies in turn led to significant reductions in the levels of soluble and insoluble total tau, and hyperphosphorylated tau as well as insoluble Aβ 42 , within the brains of bigenic T5x mice. Conclusions AV-1959R and AV-1980R formulated with Advax CpG adjuvant are immunogenic and therapeutically potent vaccines that in combination can effectively reduce both of the hallmark pathologies of AD in bigenic mice. Taken together, these findings warrant further development of this vaccine technology for ultimate testing in human AD.
44
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Clifford R. Jack, David S. Knopman, William J. Jagust et al. · The Lancet Neurology · 2009 · 4.8K citations · Full text
Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles
Salvatore Oddo, Antonella Caccamo, Jason D. Shepherd et al. · Neuron · 2003 · 4.1K citations · Full text
Holly D. Oakley, Sarah L. Cole, Sreemathi Logan et al. · Journal of Neuroscience · 2006 · 3.6K citations · Full text
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Jeff Sevigny, Ping Chiao, Thierry Bussière et al. · Nature · 2016 · 3.1K citations